Sébastien Anguille

5.1k citations

88 papers · 2.7k indexed · 1 hit paper · h-index 29

Immunology top 1%
Oncology top 2%
Molecular Biology top 10%
Hematology top 2%
Genetics top 10%

Co-authors: Viggo Van Tendeloo Zwi Berneman Evelien Smits Eva Lion Heleen H. Van Acker Yannick Willemen Gils Roex Diana Campillo-Davó
Topics: CAR-T cell therapy research (45 papers)Immunotherapy and Immune Responses (35 papers)Immune Cell Function and Interaction (23 papers)
Cited by: Immunology Oncology Hematology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
Partner nations: Belgium Netherlands United States

In The Last Decade

Sébastien Anguille

82 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical use of dendritic cells for cancer therapy

2014 541 citations Sébastien Anguille, Evelien Smits et al. profile →

Peers

Countries citing papers authored by Sébastien Anguille

Since Specialization

Citations

This map shows the geographic impact of Sébastien Anguille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sébastien Anguille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sébastien Anguille more than expected).

Fields of papers citing papers by Sébastien Anguille

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sébastien Anguille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sébastien Anguille. The network helps show where Sébastien Anguille may publish in the future.

Co-authorship network of co-authors of Sébastien Anguille

This figure shows the co-authorship network connecting the top 25 collaborators of Sébastien Anguille. A scholar is included among the top collaborators of Sébastien Anguille based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sébastien Anguille. Sébastien Anguille is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia 2025 ·Leukemia ·Daniel A. Pollyea,Tessa Kerre,Dries Deeren,Y Beguin,Tara L. Lin,David A. Sallman,Sébastien Anguille,William Blum,(unknown),Eytan Breman,Caroline Lonez	1
2	Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma 2024 ·Blood ·Marie José Kersten,(unknown),Évelyne Willems,Marte C. Liefaard,Stavros Milatos,Margot J. Pont,(unknown),Eva Santermans,(unknown),Jeevan K. Shetty,Esmée P. Hoefsmit,Omotayo Fasan,Maria T. Kuipers,Sébastien Anguille,Joost S.P. Vermaat	1
3	Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives 2024 ·SHILAP Revista de lepidopterología ·(unknown),Stef Meers,(unknown),(unknown),Koen Theunissen,Koen Van Eygen,Nathan De Beule,(unknown),(unknown),(unknown),Jan Lemmens,Ann Van de Velde,Dominik Selleslag,Jason Bouziotis,Ann De Becker,Sébastien Anguille	0
4	Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study 2024 ·PLoS ONE ·Jolien Van den Bossche,(unknown),(unknown),Paul Germonpré,Y. Valcke,(unknown),Barbara Stein,(unknown),(unknown),(unknown),Ella Roelant,Sébastien Anguille,Eva Lion,Zwi Berneman	4
5	In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells 2023 ·STAR Protocols ·(unknown),(unknown),(unknown),(unknown),Hans De Reu,Diana Campillo-Davó,Yannick Willemen,Benson Ogunjimi,Viggo Van Tendeloo,Zwi Berneman,Sébastien Anguille,Evelien Smits,Eva Lion	2
6	Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma 2023 ·Blood ·Niels W.C.J. van de Donk,Sébastien Anguille,Jo Caers,Marte C. Liefaard,Christian Jacques,(unknown)	1
7	One-step CRISPR-Cas9-mediated knockout of native TCRαβ genes in human T cells using RNA electroporation 2023 ·STAR Protocols ·(unknown),Diana Campillo-Davó,(unknown),Gils Roex,Jorrit De Waele,Sébastien Anguille,Eva Lion	1
8	Combined Results of Two Cross-Sectional Surveys on the Participation in Clinical Trials and the e-Consent Procedure in the Landscape of Haematology 2023 ·SHILAP Revista de lepidopterología ·(unknown),Stef Meers,Ann Van de Velde,Sébastien Anguille	0
9	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma 2020 ·Journal of Hematology & Oncology ·Gils Roex,(unknown),Kristien Wouters,Diana Campillo-Davó,(unknown),Wilfried Schroyens,Yiwei Chu,Zwi Berneman,Eva Lion,Feifei Luo,Sébastien Anguille	123
10	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15 2019 ·Cancers ·Heleen H. Van Acker,Zoë P. Van Acker,(unknown),Peter Ponsaerts,Daniela Pende,Zwi Berneman,Sébastien Anguille,Viggo Van Tendeloo,Evelien Smits	8
11	Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials 2015 ·Pharmacology & Therapeutics ·Heleen H. Van Acker,Sébastien Anguille,Yannick Willemen,Evelien Smits,Viggo Van Tendeloo	167
12	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy 2015 ·Pharmacological Reviews ·Sébastien Anguille,Evelien Smits,Christian Bryant,Heleen H. Van Acker,Herman Goossens,Eva Lion,Phillip D. Fromm,Derek N.J. Hart,Viggo Van Tendeloo,Zwi Berneman	122
13	Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy 2015 ·OncoImmunology ·Heleen H. Van Acker,Sébastien Anguille,Viggo Van Tendeloo,Eva Lion	52
14	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells 2014 ·Transplantation ·Amaryllis H. Van Craenenbroeck,Evelien Smits,Sébastien Anguille,Ann Van de Velde,Barbara Stein,Tessa Braeckman,(unknown),Griet Nijs,Margareta Ieven,Herman Goossens,Zwi Berneman,Viggo Van Tendeloo,Gert A. Verpooten,Pierre Van Damme,Nathalie Cools	25
15	Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo 2013 ·Molecular Therapy — Nucleic Acids ·Daphné Benteyn,Sébastien Anguille,Sandra Van Lint,Carlo Heirman,An M. T. Van Nuffel,Jurgen Corthals,Sebastian Ochsenreither,Wim Waelput,Katrien Van Beneden,Karine Breckpot,Viggo Van Tendeloo,Kris Thielemans,Aude Bonehill	40
16	Vaccination thérapeutique à base de cellules dendritiques contre la leucémie aiguë myéloïde 2012 ·Bulletin du Cancer ·Sébastien Anguille,Viggo Van Tendeloo,Zwi Berneman	4
17	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential 2012 ·PLoS ONE ·Sébastien Anguille,Eva Lion,Jurjen Tel,I. Jolanda M. de Vries,(unknown),Phillip D. Fromm,Viggo Van Tendeloo,Evelien Smits,Zwi Berneman	47
18	Interferon-α in acute myeloid leukemia: an old drug revisited 2011 ·Leukemia ·Sébastien Anguille,Eva Lion,Yannick Willemen,Viggo Van Tendeloo,Zwi Berneman,Evelien Smits	88
19	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers 2011 ·Human Vaccines ·Sébastien Anguille,Eva Lion,Evelien Smits,Zwi Berneman,Viggo Van Tendeloo	26
20	An unusual presentation of gallstone disease 2010 ·QJM ·Sébastien Anguille	1

About Sébastien Anguille

Sébastien Anguille is a scholar working on Immunology, Oncology and Hematology, having authored 88 papers that have together received 2.7k indexed citations. Recurring topics across this work include CAR-T cell therapy research (45 papers), Immunotherapy and Immune Responses (35 papers) and Immune Cell Function and Interaction (23 papers). The work is most often cited by research in Immunology (1.7k citations), Oncology (1.5k citations) and Hematology (426 citations). Sébastien Anguille has collaborated with scholars based in Belgium, Netherlands and United States. Frequent co-authors include Viggo Van Tendeloo, Zwi Berneman, Evelien Smits, Eva Lion, Heleen H. Van Acker, Yannick Willemen, Gils Roex, Diana Campillo-Davó, Herman Goossens and Jurjen Tel. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact